Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 4/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406498 | 1.00 | SLC5A2 (0.41) | SLC5A2SLC5A1ADORA3ADORA2A | |
| SCHEMBL6465802 | 0.92 | SLC5A2 (0.39) | SLC5A2SLC5A1ADORA2A | |
| SCHEMBL3411019 | 0.92 | SLC5A2 (0.39) | SLC5A2SLC5A1ADORA2A | |
| SCHEMBL6464651 | 0.89 | SLC5A2 (0.40) | SLC5A2SLC5A1ADORA3 | |
| SCHEMBL3409214 | 0.89 | SLC5A2 (0.40) | SLC5A2SLC5A1ADORA3 | |
| SCHEMBL3410072 | 0.89 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL3407888 | 0.89 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL6468147 | 0.88 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL3407259 | 0.88 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL4332311 | 0.86 | SLC5A2 (0.41) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2009-04-23 | — | — | US | claimed |
| US-7094764-B2 | Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-22 | — | — | US | claimed |
| US-7816330-B2 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004188-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2010-01-07 | — | — | US | disclosed |
| EP-1679966-A4 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2009-04-23 | — | — | US | disclosed |
| US-7511020-B2 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060234954-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | Tanabe Pharma Corporation (JP) | 2006-10-19 | — | — | US | disclosed |
| US-7094764-B2 | Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-22 | — | — | US | disclosed |
| EP-1679966-A2 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012242-A2 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | GANAB, GCG, B3GAT3 | SLC5A2 16/4885SLC5A1 18/4885ADORA3 3725/4885 |
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | GANAB, GCG, GANC | SLC5A2 18/4885SLC5A1 19/4885ADORA3 3721/4885 |
| US-20100004188-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | GANAB, GCG, GANC | SLC5A2 18/4885SLC5A1 19/4885ADORA3 3721/4885 |
| US-20060234954-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | GANAB, GCG, B3GAT3 | SLC5A2 16/4885SLC5A1 17/4885ADORA3 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.